Assembly Biosciences (NASDAQ:ASMB) reported quarterly losses of $(0.55) per share. This is a 389.47 percent decrease over earnings of $0.19 per share from the same period last year.
Belite Bio Seeks FDA Clearance For Late-Stage Genetic Eye Disease Study
Belite Bio (NASDAQ: BLTE) submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to support Phase 3 development of its lead asset LBS-008 for treatment of Stargardt Disease (STGD1).
